Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics, Inc.

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.

For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines

Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.

Perceptive Advisors

Jennison Associates

Surveyor Capital

T. Rowe Price

venBio Select Advisor

Cowen Investment Management

Deerfield Capital Management

Fidelity Management and Research Company

Franklin Templeton

Gilead Sciences

Allogene Therapeutics

Today, we honor the remarkable legacy of Dr. Martin Luther King Jr. His tireless dedication to equality, justice, and unity continues to inspire generations. $ALLO #MLK #DEIB

We look forward to presenting at the 42nd annual J.P. Morgan Healthcare Conference. Join us live or tune in to our webcast on Wednesday, January 10 at 8:15 am PT to learn more about our 2024 Vision and plans to redefine the future of CAR T. $ALLO #CART https://lnkd.in/eutcVm_C

We are pleased to announce a strategic partnership with Foresight Diagnostics Inc. The ability to pair our investigational "off-the-shelf" CAR T product with an accurate biomarker has provided the pathway to introduce CAR T in first-line LBCL. https://lnkd.in/guh_r569

Today Allogene announced a bold 2024 Platform Vision that aims to redefine the future of CAR T by leveraging the unique attributes of an allogeneic product. #CART $ALL0 https://lnkd.in/gC-qW-8P

Learn more about Allogene's 2024 Platform Vision and plans to redefine the future of CAR T. Join our upcoming conference call tomorrow at 2pm PT. https://lnkd.in/ga_kkBK5

Always grateful to get our team together for some much-deserved fun at the end of a busy year. Wishing you all safe and happy holiday!

Greater access to CAR T means both efficiacy and safety must be addressed. See our latest research at #ASH2023 booth #3205
https://lnkd.in/gDPBDdRD

The countdown to #ASH23 has begun! Visit our exhibit at booth #3205 and learn how AlloCAR T™ product candidates could fuel the next wave in cell therapy.

As CAR Ts change the treatment landscape, patient demand is straining the system. Could an "off-the-shelf” CAR T product usher in the next treatment wave? #CART #STATSummit2023

The #CART Story is far from being fully written! Our EVP of R&D and CMO, Zachary J Roberts MD PhD shares, "My hope for the future of cancer treatment is that we as a community continue to make breakthroughs that bring us closer to a cure."

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue				38.49M -	243K 99.37%	95K 60.91%
cost of revenue
gross profit				38.49M -	243K 99.37%	95K 60.91%
selling and marketing expenses
general and administrative expenses	40.98M -	57.47M 40.24%	65.26M 13.54%	74.11M 13.56%	79.31M 7.02%	71.67M 9.62%
selling general and administrative expenses	40.98M -	57.47M 40.24%	65.26M 13.54%	74.11M 13.56%	79.31M 7.02%	71.67M 9.62%
research and development expenses	151.86M -	144.53M 4.82%	192.99M 33.52%	220.18M 14.09%	256.39M 16.45%	242.91M 5.25%
other expenses	-21.21M -	-268K 98.74%	-1.14M 326.12%	-2.93M 156.30%	-1.75M 40.25%	-17.84M 919.73%
cost and expenses	192.84M -	202.01M 4.75%	258.24M 27.84%	294.28M 13.96%	335.69M 14.07%	314.59M 6.29%
operating expenses	192.84M -	202.01M 4.75%	258.24M 27.84%	294.28M 13.96%	335.69M 14.07%	314.59M 6.29%
interest expense	3.36M -				-17.11M -
ebitda	-208.26M -	-184.93M 11.21%	-258.24M 39.65%	-255.79M 0.95%	-335.45M 31.14%	-287.05M 14.43%
operating income	-192.84M -	-202.01M 4.75%	-258.24M 27.84%	-255.79M 0.95%	-335.45M 31.14%	-314.49M 6.25%
depreciation and amortization	1.50M -	17.08M 1,038.87%	7.59M 55.59%	10.45M 37.81%	14.29M 36.74%	14.20M 0.67%
total other income expenses net	-21.21M -	17.08M 180.54%	8.02M 53.04%	-1.21M 115.12%	2.82M 332.23%	-12.77M 553.43%
income before tax	-211.62M -	-184.93M 12.62%	-250.22M 35.31%	-257.00M 2.71%	-332.63M 29.43%	-327.26M 1.61%
income tax expense	-117K -	-331K 182.91%	-16.75M 4,960.42%	-12.17M 27.36%	-2.82M 76.85%	13.24M 570.18%
net income	-211.50M -	-184.59M 12.72%	-233.47M 26.48%	-244.84M 4.87%	-329.81M 34.71%	-327.26M 0.77%
weighted average shs out	28.95M -	101.06M 249.11%	120.37M 19.11%	135.82M 12.84%	143.15M 5.39%	156.93M 9.63%
weighted average shs out dil	28.95M -	101.06M 249.11%	120.37M 19.11%	135.82M 12.84%	143.15M 5.39%	156.93M 9.63%
eps	-7.31 -	-1.83 74.97%	-1.94 6.01%	-1.80 7.22%	-2.30 27.78%	-2.09 9.13%
epsdiluted	-7.31 -	-1.83 74.97%	-1.94 6.01%	-1.80 7.22%	-2.30 27.78%	-2.09 9.13%

COM:ALLOGENE

Allogene Therapeutics, Inc.

Last Close

2.11

22/11 21:00

Market Cap

498.99M

Beta: -

Volume Today

1.42M

Avg: -

Preview